$ABBV
AbbVie Inc.

2023 Q2 Form 10-Q Financial Statement

#000155115223000023 Filed on May 05, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $13.87B $12.23B
YoY Change -4.92% -9.7%
Cost Of Revenue $4.192B $3.971B
YoY Change 0.53% -2.0%
Gross Profit $9.673B $8.254B
YoY Change -7.11% -12.99%
Gross Profit Margin 69.77% 67.52%
Selling, General & Admin $3.174B $2.995B
YoY Change -41.35% -4.22%
% of Gross Profit 32.81% 36.29%
Research & Development $1.728B $2.290B
YoY Change 7.4% 52.97%
% of Gross Profit 17.86% 27.74%
Depreciation & Amortization $190.0M $179.0M
YoY Change -6.4% -9.6%
% of Gross Profit 1.96% 2.17%
Operating Expenses $4.733B $5.275B
YoY Change -32.59% 14.08%
Operating Profit $4.940B $2.979B
YoY Change 49.92% -36.85%
Interest Expense -$491.0M -$489.0M
YoY Change -188.31% -189.23%
% of Operating Profit -9.94% -16.41%
Other Income/Expense, Net -$1.412B -$1.804B
YoY Change -7.89% -332.47%
Pretax Income $2.610B $475.0M
YoY Change 120.63% -90.36%
Income Tax $583.0M $234.0M
% Of Pretax Income 22.34% 49.26%
Net Earnings $2.024B $239.0M
YoY Change 119.05% -94.68%
Net Earnings / Revenue 14.6% 1.96%
Basic Earnings Per Share $1.14 $0.13
Diluted Earnings Per Share $1.14 $0.13
COMMON SHARES
Basic Shares Outstanding 1.764B shares 1.769B shares
Diluted Shares Outstanding 1.771B shares 1.776B shares

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.766B $6.722B
YoY Change -12.0% -11.23%
Cash & Equivalents $8.759B $6.711B
Short-Term Investments $7.000M $11.00M
Other Short-Term Assets $4.540B $4.460B
YoY Change 0.75% -5.53%
Inventory $4.055B $3.833B
Prepaid Expenses
Receivables $11.49B $11.47B
Other Receivables $0.00 $0.00
Total Short-Term Assets $28.85B $26.49B
YoY Change -0.85% -0.08%
LONG-TERM ASSETS
Property, Plant & Equipment $4.943B $4.931B
YoY Change -0.3% -2.84%
Goodwill $32.22B $32.22B
YoY Change 0.61% -0.24%
Intangibles $62.86B $64.85B
YoY Change -12.48% -12.35%
Long-Term Investments $288.0M $257.0M
YoY Change 18.03% -1.15%
Other Assets $6.198B $5.800B
YoY Change 23.15% 14.11%
Total Long-Term Assets $106.5B $108.1B
YoY Change -6.64% -7.41%
TOTAL ASSETS
Total Short-Term Assets $28.85B $26.49B
Total Long-Term Assets $106.5B $108.1B
Total Assets $135.4B $134.5B
YoY Change -5.46% -6.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $27.04B $24.79B
YoY Change 19.93% 9.84%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $1.000M
YoY Change -100.0% -91.67%
Long-Term Debt Due $5.203B $2.800B
YoY Change -56.33% -71.83%
Total Short-Term Liabilities $32.24B $27.59B
YoY Change -6.48% -15.16%
LONG-TERM LIABILITIES
Long-Term Debt $55.81B $59.29B
YoY Change -8.51% -6.66%
Other Long-Term Liabilities $32.29B $32.25B
YoY Change 4.96% 15.08%
Total Long-Term Liabilities $32.29B $32.25B
YoY Change 4.96% 15.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.24B $27.59B
Total Long-Term Liabilities $32.29B $32.25B
Total Liabilities $64.53B $59.84B
YoY Change -1.09% -1.16%
SHAREHOLDERS EQUITY
Retained Earnings $1.789B $2.393B
YoY Change -49.12% -53.11%
Common Stock $19.84B $19.62B
YoY Change 4.93% 4.74%
Preferred Stock
YoY Change
Treasury Stock (at cost) $6.528B $6.524B
YoY Change 42.19% 42.29%
Treasury Stock Shares
Shareholders Equity $12.87B $13.27B
YoY Change
Total Liabilities & Shareholders Equity $135.4B $134.5B
YoY Change -5.46% -6.05%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income $2.024B $239.0M
YoY Change 119.05% -94.68%
Depreciation, Depletion And Amortization $190.0M $179.0M
YoY Change -6.4% -9.6%
Cash From Operating Activities $6.319B $4.193B
YoY Change 26.25% -14.57%
INVESTING ACTIVITIES
Capital Expenditures $178.0M $175.0M
YoY Change -224.48% 8.02%
Acquisitions $0.00 $0.00
YoY Change
Other Investing Activities -$163.0M -$26.00M
YoY Change -159.71% -83.12%
Cash From Investing Activities -$341.0M -$499.0M
YoY Change -362.31% -68.64%
FINANCING ACTIVITIES
Cash Dividend Paid $2.661B
YoY Change 5.34%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.920B -$6.192B
YoY Change 46.32% -11.19%
NET CHANGE
Cash From Operating Activities 6.319B $4.193B
Cash From Investing Activities -341.0M -$499.0M
Cash From Financing Activities -3.920B -$6.192B
Net Change In Cash 2.058B -$2.490B
YoY Change -16.21% -31.74%
FREE CASH FLOW
Cash From Operating Activities $6.319B $4.193B
Capital Expenditures $178.0M $175.0M
Free Cash Flow $6.141B $4.018B
YoY Change 19.29% -15.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001551152
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-35565
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
AbbVie Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0375147
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1 North Waukegan Road
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
North Chicago
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
60064-6400
CY2023Q1 dei City Area Code
CityAreaCode
847
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
932-7900
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1764289680 shares
CY2023Q1 us-gaap Revenues
Revenues
12225000000 usd
CY2022Q1 us-gaap Revenues
Revenues
13538000000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3986000000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4052000000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3039000000 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3127000000 usd
CY2023Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2292000000 usd
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1497000000 usd
CY2023Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
150000000 usd
CY2022Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
145000000 usd
CY2023Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
10000000 usd
CY2022Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
9457000000 usd
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
8821000000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
2768000000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
4717000000 usd
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-454000000 usd
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-539000000 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-35000000 usd
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-25000000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1804000000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
776000000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
475000000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4929000000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
234000000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
436000000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
241000000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
4493000000 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
2000000 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
3000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
239000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
4490000000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.52
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.51
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1770000000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1771000000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1776000000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1778000000 shares
CY2023Q1 us-gaap Profit Loss
ProfitLoss
241000000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
4493000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
12000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-7000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
194000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-231000000 usd
CY2023Q1 abbv Other Comprehensive Income Loss Net Investment Hedge Tax
OtherComprehensiveIncomeLossNetInvestmentHedgeTax
-60000000 usd
CY2022Q1 abbv Other Comprehensive Income Loss Net Investment Hedge Tax
OtherComprehensiveIncomeLossNetInvestmentHedgeTax
37000000 usd
CY2023Q1 abbv Other Comprehensive Income Loss Net Investment Hedge Gain Loss After Reclassificationand Tax
OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax
-224000000 usd
CY2022Q1 abbv Other Comprehensive Income Loss Net Investment Hedge Gain Loss After Reclassificationand Tax
OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax
130000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
-14000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
-10000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-38000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-28000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
-4000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
-2000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-41000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-12000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-33000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-85000000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
208000000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
4408000000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
2000000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
3000000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
206000000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4405000000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6711000000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9201000000 usd
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
11000000 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
28000000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11473000000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11254000000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
3833000000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
3579000000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
4460000000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
4401000000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
26488000000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
28463000000 usd
CY2023Q1 us-gaap Long Term Investments
LongTermInvestments
257000000 usd
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
241000000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4931000000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4935000000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
64848000000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
67439000000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
32220000000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
32156000000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5800000000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5571000000 usd
CY2023Q1 us-gaap Assets
Assets
134544000000 usd
CY2022Q4 us-gaap Assets
Assets
138805000000 usd
CY2023Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
1000000 usd
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
1000000 usd
CY2023Q1 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
2800000000 usd
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
4135000000 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
24789000000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
25402000000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
27590000000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
29538000000 usd
CY2023Q1 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
59292000000 usd
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
59135000000 usd
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2110000000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2190000000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
32249000000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
30655000000 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4000000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4000000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1821082016 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1813770294 shares
CY2023Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
18000000 usd
CY2022Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
18000000 usd
CY2023Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
57113024 shares
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
44589000 shares
CY2023Q1 us-gaap Treasury Stock Value
TreasuryStockValue
6524000000 usd
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
4594000000 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
19619000000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
19245000000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2393000000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
4784000000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2232000000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2199000000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
13274000000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17254000000 usd
CY2023Q1 us-gaap Minority Interest
MinorityInterest
29000000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
33000000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
13303000000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17287000000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
134544000000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
138805000000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
15436000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
4490000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-85000000 usd
CY2022Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
2514000000 usd
CY2022Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1470000000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
454000000 usd
CY2022Q1 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
3000000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
16314000000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17287000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
239000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-33000000 usd
CY2023Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
2630000000 usd
CY2023Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1955000000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
399000000 usd
CY2023Q1 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-4000000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
13303000000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
241000000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
4493000000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
179000000 usd
CY2022Q1 us-gaap Depreciation
Depreciation
198000000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1948000000 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1855000000 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-267000000 usd
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-194000000 usd
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1872000000 usd
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-748000000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
313000000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
306000000 usd
CY2023Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
150000000 usd
CY2022Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
145000000 usd
CY2023Q1 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
710000000 usd
CY2022Q1 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 usd
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
128000000 usd
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-128000000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
195000000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
785000000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
185000000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
385000000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
167000000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
285000000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-465000000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-258000000 usd
CY2023Q1 us-gaap Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
187000000 usd
CY2022Q1 us-gaap Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
438000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4193000000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4908000000 usd
CY2023Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
353000000 usd
CY2022Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
185000000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
175000000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
162000000 usd
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
19000000 usd
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1406000000 usd
CY2023Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
22000000 usd
CY2022Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
8000000 usd
CY2023Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-26000000 usd
CY2022Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-154000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-499000000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1591000000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
2000000000 usd
CY2023Q1 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
1351000000 usd
CY2022Q1 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
4879000000 usd
CY2023Q1 us-gaap Payments Of Dividends
PaymentsOfDividends
2661000000 usd
CY2022Q1 us-gaap Payments Of Dividends
PaymentsOfDividends
2526000000 usd
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1955000000 usd
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1470000000 usd
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
65000000 usd
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
128000000 usd
CY2023Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
311000000 usd
CY2022Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
246000000 usd
CY2023Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
21000000 usd
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
21000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-6192000000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-6972000000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8000000 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7000000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2490000000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3648000000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9201000000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9746000000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6711000000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6098000000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
553000000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
548000000 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
99000000 usd
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
9000000 usd
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-454000000 usd
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-539000000 usd
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1319000000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1162000000 usd
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1312000000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1417000000 usd
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1202000000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1000000000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
3833000000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
3579000000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
228000000 usd
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11142000000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10986000000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6211000000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6051000000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4931000000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4935000000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
179000000 usd
CY2022Q1 us-gaap Depreciation
Depreciation
198000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
239000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
4490000000 usd
CY2023Q1 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Basic
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
11000000 usd
CY2022Q1 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Basic
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
22000000 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4468000000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1770000000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1771000000 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.52
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
239000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
4490000000 usd
CY2023Q1 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
11000000 usd
CY2022Q1 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
22000000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
228000000 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
4468000000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1770000000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1771000000 shares
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
6000000 shares
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
7000000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1776000000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1778000000 shares
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.51
CY2023Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
353000000 usd
CY2022Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
185000000 usd
CY2023Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
150000000 usd
CY2022Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
145000000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
32156000000 usd
CY2023Q1 us-gaap Goodwill Other Increase Decrease
GoodwillOtherIncreaseDecrease
64000000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
32220000000 usd
CY2023Q1 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
96096000000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
31537000000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
64559000000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
96172000000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
29645000000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
66527000000 usd
CY2023Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
289000000 usd
CY2023Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
289000000 usd
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
912000000 usd
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
912000000 usd
CY2023Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
96385000000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
31537000000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
64848000000 usd
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
97084000000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
29645000000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
67439000000 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1900000000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1900000000 usd
CY2022Q1 us-gaap Gain Loss From Components Excluded From Assessment Of Fair Value Hedge Effectiveness Net
GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet
0 usd
CY2023Q1 us-gaap Gain Loss From Components Excluded From Assessment Of Cash Flow Hedge Effectiveness Net
GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet
0 usd
CY2023Q1 us-gaap Gain Loss From Components Excluded From Assessment Of Fair Value Hedge Effectiveness Net
GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet
0 usd
CY2022Q1 us-gaap Gain Loss From Components Excluded From Assessment Of Cash Flow Hedge Effectiveness Net
GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet
0 usd
CY2023Q1 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
161000000 usd
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
163000000 usd
CY2023Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
544000000 usd
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
524000000 usd
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 usd
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0 usd
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0 usd
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
16384000000 usd
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
14887000000 usd
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-1872000000 usd
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
748000000 usd
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
325000000 usd
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
321000000 usd
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
17931000000 usd
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
13818000000 usd
CY2023Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
115000000 usd
CY2022Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
129000000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
258000000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
313000000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
306000000 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
55000000 usd
CY2022Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
56000000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
250000000 usd
CY2023Q1 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
4800000000 usd
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.49
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.09
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q1 us-gaap Decrease In Unrecognized Tax Benefits Is Reasonably Possible
DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
110000000 usd
CY2023Q1 us-gaap Revenues
Revenues
12225000000 usd
CY2022Q1 us-gaap Revenues
Revenues
13538000000 usd

Files In Submission

Name View Source Status
0001551152-23-000023-index-headers.html Edgar Link pending
0001551152-23-000023-index.html Edgar Link pending
0001551152-23-000023.txt Edgar Link pending
0001551152-23-000023-xbrl.zip Edgar Link pending
abbv-20230331.htm Edgar Link pending
abbv-20230331.xsd Edgar Link pending
abbv-20230331xex101.htm Edgar Link pending
abbv-20230331xex101001.jpg Edgar Link pending
abbv-20230331xex101002.jpg Edgar Link pending
abbv-20230331xex101003.jpg Edgar Link pending
abbv-20230331xex101004.jpg Edgar Link pending
abbv-20230331xex101005.jpg Edgar Link pending
abbv-20230331xex101006.jpg Edgar Link pending
abbv-20230331xex101007.jpg Edgar Link pending
abbv-20230331xex101008.jpg Edgar Link pending
abbv-20230331xex101009.jpg Edgar Link pending
abbv-20230331xex101010.jpg Edgar Link pending
abbv-20230331xex101011.jpg Edgar Link pending
abbv-20230331xex101012.jpg Edgar Link pending
abbv-20230331xex101013.jpg Edgar Link pending
abbv-20230331xex101014.jpg Edgar Link pending
abbv-20230331xex101015.jpg Edgar Link pending
abbv-20230331xex101016.jpg Edgar Link pending
abbv-20230331xex101017.jpg Edgar Link pending
abbv-20230331xex101018.jpg Edgar Link pending
abbv-20230331xex101019.jpg Edgar Link pending
abbv-20230331xex101020.jpg Edgar Link pending
abbv-20230331xex101021.jpg Edgar Link pending
abbv-20230331xex101022.jpg Edgar Link pending
abbv-20230331xex101023.jpg Edgar Link pending
abbv-20230331xex101024.jpg Edgar Link pending
abbv-20230331xex101025.jpg Edgar Link pending
abbv-20230331xex101026.jpg Edgar Link pending
abbv-20230331xex101027.jpg Edgar Link pending
abbv-20230331xex101028.jpg Edgar Link pending
abbv-20230331xex101029.jpg Edgar Link pending
abbv-20230331xex101030.jpg Edgar Link pending
abbv-20230331xex101031.jpg Edgar Link pending
abbv-20230331xex101032.jpg Edgar Link pending
abbv-20230331xex102.htm Edgar Link pending
abbv-20230331xex102001.jpg Edgar Link pending
abbv-20230331xex102002.jpg Edgar Link pending
abbv-20230331xex102003.jpg Edgar Link pending
abbv-20230331xex102004.jpg Edgar Link pending
abbv-20230331xex102005.jpg Edgar Link pending
abbv-20230331xex102006.jpg Edgar Link pending
abbv-20230331xex102007.jpg Edgar Link pending
abbv-20230331xex102008.jpg Edgar Link pending
abbv-20230331xex102009.jpg Edgar Link pending
abbv-20230331xex102010.jpg Edgar Link pending
abbv-20230331xex102011.jpg Edgar Link pending
abbv-20230331xex102012.jpg Edgar Link pending
abbv-20230331xex102013.jpg Edgar Link pending
abbv-20230331xex102014.jpg Edgar Link pending
abbv-20230331xex102015.jpg Edgar Link pending
abbv-20230331xex102016.jpg Edgar Link pending
abbv-20230331xex102017.jpg Edgar Link pending
abbv-20230331xex102018.jpg Edgar Link pending
abbv-20230331xex102019.jpg Edgar Link pending
abbv-20230331xex102020.jpg Edgar Link pending
abbv-20230331xex102021.jpg Edgar Link pending
abbv-20230331xex102022.jpg Edgar Link pending
abbv-20230331xex102023.jpg Edgar Link pending
abbv-20230331xex102024.jpg Edgar Link pending
abbv-20230331xex102025.jpg Edgar Link pending
abbv-20230331xex102026.jpg Edgar Link pending
abbv-20230331xex102027.jpg Edgar Link pending
abbv-20230331xex102028.jpg Edgar Link pending
abbv-20230331xex102029.jpg Edgar Link pending
abbv-20230331xex102030.jpg Edgar Link pending
abbv-20230331xex102031.jpg Edgar Link pending
abbv-20230331xex103.htm Edgar Link pending
abbv-20230331xex103001.jpg Edgar Link pending
abbv-20230331xex103002.jpg Edgar Link pending
abbv-20230331xex103003.jpg Edgar Link pending
abbv-20230331xex103004.jpg Edgar Link pending
abbv-20230331xex103005.jpg Edgar Link pending
abbv-20230331xex103006.jpg Edgar Link pending
abbv-20230331xex103007.jpg Edgar Link pending
abbv-20230331xex103008.jpg Edgar Link pending
abbv-20230331xex104.htm Edgar Link pending
abbv-20230331xex104001.jpg Edgar Link pending
abbv-20230331xex104002.jpg Edgar Link pending
abbv-20230331xex104003.jpg Edgar Link pending
abbv-20230331xex104004.jpg Edgar Link pending
abbv-20230331xex104005.jpg Edgar Link pending
abbv-20230331xex104006.jpg Edgar Link pending
abbv-20230331xex104007.jpg Edgar Link pending
abbv-20230331xex104008.jpg Edgar Link pending
abbv-20230331xex104009.jpg Edgar Link pending
abbv-20230331xex104010.jpg Edgar Link pending
abbv-20230331xex104011.jpg Edgar Link pending
abbv-20230331xex104012.jpg Edgar Link pending
abbv-20230331xex104013.jpg Edgar Link pending
abbv-20230331xex104014.jpg Edgar Link pending
abbv-20230331xex104015.jpg Edgar Link pending
abbv-20230331xex104016.jpg Edgar Link pending
abbv-20230331xex104017.jpg Edgar Link pending
abbv-20230331xex104018.jpg Edgar Link pending
abbv-20230331xex104019.jpg Edgar Link pending
abbv-20230331xex104020.jpg Edgar Link pending
abbv-20230331xex104021.jpg Edgar Link pending
abbv-20230331xex104022.jpg Edgar Link pending
abbv-20230331xex104023.jpg Edgar Link pending
abbv-20230331xex104024.jpg Edgar Link pending
abbv-20230331xex104025.jpg Edgar Link pending
abbv-20230331xex104026.jpg Edgar Link pending
abbv-20230331xex104027.jpg Edgar Link pending
abbv-20230331xex104028.jpg Edgar Link pending
abbv-20230331xex105.htm Edgar Link pending
abbv-20230331xex105001.jpg Edgar Link pending
abbv-20230331xex105002.jpg Edgar Link pending
abbv-20230331xex105003.jpg Edgar Link pending
abbv-20230331xex105004.jpg Edgar Link pending
abbv-20230331xex105005.jpg Edgar Link pending
abbv-20230331xex105006.jpg Edgar Link pending
abbv-20230331xex105007.jpg Edgar Link pending
abbv-20230331xex105008.jpg Edgar Link pending
abbv-20230331xex105009.jpg Edgar Link pending
abbv-20230331xex105010.jpg Edgar Link pending
abbv-20230331xex105011.jpg Edgar Link pending
abbv-20230331xex105012.jpg Edgar Link pending
abbv-20230331xex105013.jpg Edgar Link pending
abbv-20230331xex105014.jpg Edgar Link pending
abbv-20230331xex105015.jpg Edgar Link pending
abbv-20230331xex105016.jpg Edgar Link pending
abbv-20230331xex105017.jpg Edgar Link pending
abbv-20230331xex105018.jpg Edgar Link pending
abbv-20230331xex105019.jpg Edgar Link pending
abbv-20230331xex105020.jpg Edgar Link pending
abbv-20230331xex105021.jpg Edgar Link pending
abbv-20230331xex105022.jpg Edgar Link pending
abbv-20230331xex105023.jpg Edgar Link pending
abbv-20230331xex105024.jpg Edgar Link pending
abbv-20230331xex105025.jpg Edgar Link pending
abbv-20230331xex105026.jpg Edgar Link pending
abbv-20230331xex105027.jpg Edgar Link pending
abbv-20230331xex106.htm Edgar Link pending
abbv-20230331xex106001.jpg Edgar Link pending
abbv-20230331xex106002.jpg Edgar Link pending
abbv-20230331xex106003.jpg Edgar Link pending
abbv-20230331xex106004.jpg Edgar Link pending
abbv-20230331xex106005.jpg Edgar Link pending
abbv-20230331xex106006.jpg Edgar Link pending
abbv-20230331xex106007.jpg Edgar Link pending
abbv-20230331xex106008.jpg Edgar Link pending
abbv-20230331xex106009.jpg Edgar Link pending
abbv-20230331xex106010.jpg Edgar Link pending
abbv-20230331xex106011.jpg Edgar Link pending
abbv-20230331xex106012.jpg Edgar Link pending
abbv-20230331xex106013.jpg Edgar Link pending
abbv-20230331xex106014.jpg Edgar Link pending
abbv-20230331xex311.htm Edgar Link pending
abbv-20230331xex312.htm Edgar Link pending
abbv-20230331xex321.htm Edgar Link pending
abbv-20230331xex322.htm Edgar Link pending
abbv-20230331_g1.jpg Edgar Link pending
abbv-20230331_g2.gif Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
abbv-20230331_htm.xml Edgar Link completed
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
abbv-20230331_def.xml Edgar Link unprocessable
abbv-20230331_cal.xml Edgar Link unprocessable
abbv-20230331_lab.xml Edgar Link unprocessable
abbv-20230331_pre.xml Edgar Link unprocessable